Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

ART27.13 produced approximately 40% weight loss in obese mice when combined with semaglutide over four weeks, versus roughly 20% as a monotherapy. The preclinical data suggest potential additive efficacy in obesity treatment, though translation from mouse studies to human outcomes remains uncertain.